163 related articles for article (PubMed ID: 34661906)
21. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
[TBL] [Abstract][Full Text] [Related]
22. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
[TBL] [Abstract][Full Text] [Related]
24. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
25. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
26. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
27. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
Williams CYK; Townson AT; Terry N; Schmitt NC; Sharma A
Laryngoscope; 2023 Mar; 133(3):476-484. PubMed ID: 35567387
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma.
Piao S; Zhao S; Guo F; Xue J; Yao G; Wei Z; Huang Q; Sun Y; Zhang B
J Cancer Res Clin Oncol; 2012 Apr; 138(4):627-35. PubMed ID: 22215147
[TBL] [Abstract][Full Text] [Related]
29. Parotid salivary duct carcinoma: a single institution's 20-year experience.
Stodulski D; Mikaszewski B; Majewska H; Kuczkowski J
Eur Arch Otorhinolaryngol; 2019 Jul; 276(7):2031-2038. PubMed ID: 31062093
[TBL] [Abstract][Full Text] [Related]
30. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
[TBL] [Abstract][Full Text] [Related]
31. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database.
Osborn V; Givi B; Lee A; Sheth N; Roden D; Schwartz D; Schreiber D
Oral Oncol; 2017 Aug; 71():41-46. PubMed ID: 28688689
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of adjuvant therapy on the prognosis of ductal carcinoma of the major salivary gland: a large-scale cohort study.
Zhang D; Li L; Wen T; Ma F
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):409-417. PubMed ID: 36036273
[TBL] [Abstract][Full Text] [Related]
33. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
[TBL] [Abstract][Full Text] [Related]
34. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
[TBL] [Abstract][Full Text] [Related]
35. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathological analysis of 40 cases of salivary duct carcinoma].
Lin N; Cai JH; Xu MJ; Kang P; Cheng ZF; He W
Zhonghua Kou Qiang Yi Xue Za Zhi; 2019 Jun; 54(6):416-419. PubMed ID: 31177683
[No Abstract] [Full Text] [Related]
37. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T
Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821
[TBL] [Abstract][Full Text] [Related]
38. Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities.
Rahman M; Griffith CC
Surg Pathol Clin; 2021 Mar; 14(1):111-126. PubMed ID: 33526216
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
[TBL] [Abstract][Full Text] [Related]
40. Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma.
Aoyama J; Nojima Y; Sano D; Hirai Y; Kijima N; Aizawa Y; Takada K; Hatano T; Takahashi H; Nishimura G; Oridate N
Head Neck; 2023 Jul; 45(7):1801-1811. PubMed ID: 37184432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
